Microdosing: What the Term Means (and the Law in Australia)

The law comes first, always

Psilocybin , the principal psychoactive compound in "magic mushrooms" , is classified as a Schedule 9 Prohibited Substance under Australia's Poisons Standard (the Federal Register of Legislation document that governs how drugs are scheduled nationally). Schedule 9 means the substance is considered to have unacceptably high potential for misuse and very limited, if any, legitimate medical application outside of highly controlled research or clinical contexts. Possession, use, manufacture, or supply outside those contexts is a criminal offence in every Australian state and territory.

The one narrow exception came into effect on 1 July 2023, when the Therapeutic Goods Administration (TGA) moved psilocybin , alongside MDMA; to Schedule 8 (Controlled Drug) for a specific, tightly defined purpose: use in authorised clinical settings by an Authorised Prescriber. Even then, the pathway is strict. An Authorised Prescriber must be approved by the TGA and must work within an institution that has ethics committee oversight. Patients are not walking into a GP and picking up a script. The substance is administered and monitored by clinicians. This is not a consumer pathway.

Everything outside that framework, including any self-administered microdosing practice, remains Schedule 9 prohibited. That applies whether someone obtains psilocybin locally, imports it, or grows the fungi themselves. The legal exposure is real and serious.

With that foundation set, we can talk about what "microdosing" actually means as a concept.

Defining microdosing: what the term describes

The term "microdosing" entered scientific literature primarily through psychedelic research, though it also has an older, parallel meaning in drug development (sometimes called "Phase 0 trials") where trace amounts of a compound are administered to study its pharmacokinetics in humans before full trials begin. In the psychedelic context, the word refers to something more specific: the administration of a sub-perceptual quantity of a psychedelic substance, typically psilocybin or LSD, at a dose intended to fall below the threshold that produces obvious perceptual changes.

The distinction matters. A "full" psychedelic dose produces pronounced alterations in perception, cognition, and sense of self; what researchers typically call the "psychedelic experience". A sub-perceptual or microdose, by the definition used in most published literature, is intended to produce none of those overt effects. Whether it produces any meaningful physiological or cognitive change at all is exactly what researchers are trying to establish.

Quantities described in research literature vary considerably. Published observational and placebo-controlled studies have generally examined doses in the range of roughly one-tenth to one-twentieth of a typical "full" dose, based on participant reports or study protocols, but these are figures from published scientific accounts, not instructions. Reporting them in that context is different from prescribing them, and I want to be clear: this article does not constitute dosing guidance of any kind.

The serotonin receptor connection

Psilocybin is a prodrug. After ingestion it is rapidly dephosphorylated by alkaline phosphatase to psilocin, which is the pharmacologically active form. Psilocin binds with high affinity to serotonin receptors, particularly the 5-HT2A receptor subtype; and it is this agonist activity that is understood to underlie the full psychedelic effect at higher doses.

At sub-perceptual doses, the receptor dynamics are less well characterised. There is active scientific debate about whether a dose that produces no subjective effect is also producing no meaningful receptor activity, or whether partial, low-level receptor engagement occurs below conscious awareness. This is one reason microdosing is genuinely scientifically interesting, and genuinely scientifically unresolved.

It is worth noting that the serotonergic system interacts in complex ways with the endocannabinoid system. Researchers studying cannabinoids, such as cannabidiol (CBD); have noted indirect serotonergic modulation as one of several proposed mechanisms. The two systems are not identical, but there is enough overlap that researchers in both fields sometimes end up reading each other's papers. I've found myself doing exactly that at 11pm on a Tuesday more often than I'd care to admit.

What the research actually shows (and what it doesn't)

The honest answer is: we don't know much yet, and what we think we know keeps being complicated by new data.

Early observational and survey-based studies reported that people who self-reported microdosing described improvements in mood, focus, and creativity. These were largely uncontrolled, self-selected samples, people who chose to microdose and then rated their own experience. The methodological problems are significant: placebo effects, expectation bias, and the lack of verified doses are all substantial confounds.

More rigorous placebo-controlled trials have followed. A 2022 study published in eLife (Szigeti et al., using a self-blinding methodology) found that while participants reported subjective benefits, these were not clearly distinguishable from placebo effects once blinding was properly assessed. A 2023 pre-registered study from Imperial College London, published in Neuropsychopharmacology, found that psilocybin microdosing produced measurable changes in some psychological measures but the clinical significance of those changes remains contested.

None of these studies constitute evidence that microdosing treats, prevents, or manages any health condition. The research is preliminary. The field is aware of this. I'd argue some of the popular press coverage of microdosing has run well ahead of what the data actually supports, which is a problem for public understanding and for regulatory discourse alike.

The community practice versus the clinical framework

There is a documented gap between the community-based microdosing practice that has attracted media attention and the clinical framework the TGA has established. Community accounts; widely reported in popular science books, podcasts, and online forums, describe people self-administering unverified quantities of an unregulated, often home-grown substance on informal schedules. This is categorically outside any legal framework in Australia. The Australian Drug Foundation's drug facts page on psilocybin mushrooms is explicit about the legal status and the risks, including psychological distress, adverse reactions, and interaction effects.

The clinical framework, by contrast, involves verified pharmaceutical-grade psilocybin, administered in a clinical setting, under supervision, to patients who have undergone screening and who are receiving psychological support. The Special Access Scheme pathway and the Authorised Prescriber pathway both require TGA approval and ongoing regulatory oversight. These are not comparable to informal self-experimentation, and conflating the two, as popular coverage sometimes does; understates the risk and overstates the accessibility.

Why the pharmacokinetics make sub-perceptual dosing complicated

Even setting legal questions aside, the pharmacokinetics of psilocybin create practical complexity for microdosing research. Psilocybin's conversion to psilocin, the variable bioavailability of different preparations, and individual differences in enzymatic metabolism mean that the same nominal dose can produce quite different plasma concentrations in different people. Dried mushroom material, the form most commonly described in community accounts, is additionally variable in psilocybin content by species, growing conditions, and preparation method.

This variability is a substantial obstacle to rigorous research. It also means that informal community accounts of "consistent" sub-perceptual dosing may be describing highly inconsistent pharmacological exposures. The TGA's scheduling decision from the 2022 ACMS-34 meeting addressed some of these safety considerations in the context of its rescheduling assessment.

What the rescheduling of 2023 actually changed

The 1 July 2023 rescheduling of psilocybin to Schedule 8 under the Authorised Prescriber pathway was a genuine regulatory milestone; one of the more significant in Australian psychedelic medicine policy. But it is worth being precise about its scope. The rescheduling did not decriminalise possession. It did not create a consumer market. It did not authorise GPs to prescribe psilocybin in standard clinical practice.

What it did was create a lawful pathway for specialist clinicians, with appropriate approval and ethics oversight, to access pharmaceutical-grade psilocybin for specific patients. The doses used in those clinical settings are, notably, full psychedelic doses administered in therapeutic sessions, not the sub-perceptual quantities described in community microdosing discourse. The clinical model and the microdosing model are actually quite different in their approach.

Anyone seeking to understand their own options in this space should speak with a qualified medical practitioner, not a website. That includes this one.

Sources

• Final Scheduling Decisions: ACMS-34, November 2022, Therapeutic Goods Administration (TGA)
• Magic Mushrooms Drug Facts; Australian Drug Foundation (ADF)
• Szigeti et al. (2021), "Self-blinding citizen science to explore psychedelic microdosing", eLife, via PubMed Central
• Szigeti et al. (2023), pre-registered microdosing trial findings, Neuropsychopharmacology, via PubMed Central

, Daniel Okoro, Psychedelic science & law writer